In addition, the feasibility of interfering with effector binding was demonstrated by engineering a cell‐permeable RAS‐binding domain polypeptide that achieved potent and selective anti‐tumor effects in KRAS mutant cell lines [84]. The gene discussed is KRAS; the disease is neoplasm.